100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis

Background

Colorectal cancer ranks as the third most prevalent cancer globally and stands as the second primary contributor to cancer-related mortality. Utilization of a phenomic data approach allows researchers to reveal the mechanisms and molecular pathogenesis of colorectal cancer. We aimed to investigate the correlation between the phenomic features and colorectal cancer in a large cohort study.

Methods

We included 502369 subjects aged 37-73 years in the UK Biobank recruited since 2006. In total, 59 parameters exploring socio-demographic factors, blood chemistry, anthropometric measurements and lifestyle factors of participants collected at baseline assessment were analysed. Univariate and multivariate logistic regression were conducted to examine the associations of these parameters with colorectal cancer risk, based on the odds ratio (OR) and 95% confidence intervals (CI).

Results

The analysis included a total of 438625 participants, of which 5436 (1.2%) were incident colorectal cancer cases and 433189 were healthy controls. A marker, cystatin C was associated with colorectal cancer (adjusted OR 2.11; 95% CI 1.92-2.32). Compared to Asians, Whites ethnicity had higher risk of developing colorectal cancers (adjusted OR 2.54; 95% CI 1.93-3.34). In addition to colorectal cancer, Cystatin C and ethnicity are consistently associated with total gastrointestinal cancers. Cystatin C and ethnicity appear to be important features in GI cancers, suggesting some overlap in the molecular pathogenesis of GI cancers.

Conclusions

Cystatin C and ethnicity emerged as a consistent biomarker associated with different types of gastrointestinal cancers, including colorectal cancer. In order to provide more in-depth understanding of how these factors were associated with gastrointestinal cancers and shed light on the molecular pathogenesis of gastrointestinal cancers, future research will employ a multi-modal approach exploring the genomics and proteomics of the UK Biobank cohort.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.